Extended Treatment With Vancomycin for Clostridium Difficile Colitis
Information source: William Beaumont Hospitals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Clostridium Difficile Colitis
Intervention: Standard Vancomycin (Drug); Extended Vancomycin (Drug)
Phase: N/A
Status: Withdrawn
Sponsored by: William Beaumont Hospitals
Summary
BACKGROUND: Clostridium difficile-associated colitis is an infection of the large bowel,
usually associated with previous use of antibiotics. The disease course may be complicated
by fulminant disease requiring removal of the colon or by multiple recurrences requiring
re-hospitalization. The incidence and severity of Clostridium difficile infection is rising,
and it poses an increasing burden on the health system. For example, in one of our previous
studies we found that 804 in-patients and 568 out-patients had a positive test for
Clostridium difficile toxin at Beaumont Laboratories in 2003. The standard treatment is a 2
week course of Vancomycin or Metronidazole. The clinical response to Metronidazole appears
to be declining, and many practicing clinicians prefer Vancomycin as a first-line treatment.
The recurrence rate after the treatment is similar for Vancomycin and Metronidazole and is
usually in the range of 15-25%, although recent reports noted a recurrence rate up to 50%
during outbreaks with a virulent strain. Recently, it has been suggested that a 2 week
duration of treatment might not be adequate in clearing the infection.
Our HYPOTHESIS is that a prolongation of Vancomycin treatment from 2 weeks to 4 weeks will
lead to a decrease rate of recurrent Clostridium Difficile colitis.
Clinical Details
Official title: Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: compare the incidence of recurrent Clostridium difficile-associated colitis (CDAD) after a standard 2 week versus a prolonged 4 week course of treatment with Vancomycin
Secondary outcome: assess the response rate to Vancomycin in patients with the first episode of CDAD
Detailed description:
METHODOLOGY: Patients with a first episode of Clostridium difficile colitis will be offered
a prolonged course of Vancomycin. It will be disclosed that this is not the standard of
care, but that a prolonged course might decrease the relapse rate. After the initial
treatment with Vancomycin 125 mg four times daily, the patients will be randomly assigned to
receive either 2 weeks of Vancomycin 125 mg four times daily or 2 weeks of placebo. The
placebo solution will be prepared by our pharmacy to match the color and taste of the
Vancomycin solution. The initial 2 weeks of therapy for both groups will be dispensed at
patients' pharmacy. Patients will be called back at the end of 2 weeks and the blinded-phase
drugs will be dispensed by our pharmacy staff.
We will ask permission for a follow-up phone call at the end of treatment (1 month) and at a
3-month interval. The patients will be followed longitudinally for a 3-month period. At the
end of the follow-up interval, a review of any new medical records of the patient will be
made and the patient will be contacted by phone for further details.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- First episode of Clostridium difficile colitis, defined by a positive toxin assay
plus at least one of the following: diarrhea, toxic megacolon or leukocytosis.
Exclusion Criteria:
- previous diagnosis of Clostridium difficile colitis
- concomitant use of oral Metronidazole, Rifampin, Rifaximin, Nitazoxanide,
Sacharromyce boulardii or Lactobacillus spp.
- age less than 18 years-old
- pregnancy.
Locations and Contacts
William Beaumont Hospital, Royal Oak, Michigan 48073, United States
Additional Information
Related publications: Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007 Aug 1;45(3):302-7. Epub 2007 Jun 19. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005 Jun 1;40(11):1591-7. Epub 2005 Apr 25.
Starting date: February 2009
Last updated: January 19, 2010
|
